|
|
|
Clinical TrialsNon-Small Cell Lung CancerAdvancedOSI2950g: A randomized Phase II study to evaluate the efficacy and safety of Bevacizumab (Avastin) in combination with Docetaxel (Taxotere), Pemetrexed Dosodium (Alimta) or Erlotinib Hydrochloride (Tarceva) compared with Docetaxel (Taxotere) pr Pemetrexed Disodium (Tarceva) alone for the treatment of patients with recurrent or refractory stage IIIB stage IV non-small cell lung cancer. [UCLA]
For more information on VCHOS trials, please call Ruth Ann Begun at (805) 485-8709 ext 136 or email at rbegun@venturaoncology.com.For more information on UCLA network trials, please call Pamela Riach, RN at (805) 485-8709 ext 129 or email at priach@mednet.ucla.edu.
|
|
Send mail to
webmaster@venturaoncology.com with
questions or comments about this web site.
|